If only they knew! A non-inferiority randomized controlled trial comparing deceptive and open-label placebo in healthy individuals

被引:1
|
作者
Druart, L. [1 ,2 ]
Graham Longsworth, S. E. [1 ,2 ]
Terrisse, H. [1 ]
Locher, C. [3 ]
Blease, C. [4 ]
Rolland, C. [1 ]
Pinsault, N. [1 ,2 ]
机构
[1] Univ Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup,Grenoble INP,TIMC, Grenoble, France
[2] Univ Grenoble Alpes, Dept Physiotherapy, 175 Av Centrale St Martin dHeres, F-38400 Grenoble, France
[3] Univ Hosp Zurich, Dept Consultat Liaison Psychiat & Psychosomat Med, Zurich, Switzerland
[4] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Psychiat, Digital Psychiat, Boston, MA USA
关键词
PAIN; EFFICACY;
D O I
10.1002/ejp.2204
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Placebo use is widespread in clinical practice. However, they are most often administered deceptively rather than openly. It is often suggested that open-label placebos (OLP) are less effective than deceptive placebos (DP). This study aimed to compare the use of DP and OLP treatments to reduce pain in healthy volunteers. Methods: We conducted a non-inferiority, parallel, randomized, controlled trial, which also included a nested cross-over no-treatment condition. This study was conducted at a university clinic in France. Results: We included 60 subjects and the main result shows that the OLP was not inferior to the DP by a margin of 10 mm. The mean difference between both groups regarding intensity of pain was 0.7 mm with a 95% compatibility interval (95% CI) of ]-infinity; 5.4], and 97.5% CI of ]-infinity; 6.3]. Secondary outcomes require cautious interpretation of the effect of placebo versus no treatment due to a time- treatment interaction. Conclusion: The study indicates that OLP may perform just as well as DP and could provide support for the use of OLP as an ethical alternative to DP when they are to be used in a clinical setting. If only patients knew about the placebo nature of some treatments they are receiving, unnecessary lies could be avoided while maintaining similar placebo effects. Significance: This study is the first to show non-inferiority of placebos administered honestly, also called OLP, compared to DP in reducing pain. This suggests that OLP could be as effective as their deceptive counterparts while having the ethical advantage of not being required to lie. If deception is not a necessary condition for efficacy, OLP should be preferred over DP.
引用
收藏
页码:491 / 501
页数:11
相关论文
共 50 条
  • [1] Deceptive and open-label placebo effects in experimentally induced guilt: a randomized controlled trial in healthy subjects
    Sezer, Dilan
    Locher, Cosima
    Gaab, Jens
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] Deceptive and open-label placebo effects in experimentally induced guilt: a randomized controlled trial in healthy subjects
    Dilan Sezer
    Cosima Locher
    Jens Gaab
    Scientific Reports, 12
  • [3] Efficacy of Bimin decoction for patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial
    Jingyi Zhao
    Xinyu Yan
    Jianqing Gai
    Jinshuai Han
    Hong Zhang
    Hui Luo
    Shaoting Huang
    Junge Wang
    Trials, 20
  • [4] Comparing Articaine brands: A randomized non-inferiority controlled trial
    Arboleda-Toro, D.
    Toro, L.
    Osorio-Osorno, Y. A.
    Castrillon-Pino, L.
    Florez-Zapata, N. M. V.
    HELIYON, 2021, 7 (06)
  • [5] Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa
    Olivennes, F.
    Trew, G.
    Borini, A.
    Broekmans, F.
    Arriagada, P.
    Warne, D. W.
    Howles, C. M.
    REPRODUCTIVE BIOMEDICINE ONLINE, 2015, 30 (03) : 248 - 257
  • [6] Intravenous Amoxicillin Plus Intravenous Gentamicin for Children with Severe Pneumonia in Bangladesh: An Open-Label, Randomized, Non-Inferiority Controlled Trial
    Shahrin, Lubaba
    Chisti, Mohammod Jobayer
    Sarmin, Monira
    Rahman, Abu Sayem Mirza Md. Hasibur
    Shahid, Abu Sadat Mohammad Sayeem Bin
    Islam, Md. Zahidul
    Afroze, Farzana
    Huq, Sayeeda
    Ahmed, Tahmeed
    LIFE-BASEL, 2021, 11 (12):
  • [7] A comparison of open-label and deceptive placebo analgesia in a healthy sample
    Disley, Nathan
    Kola-Palmer, Susanna
    Retzler, Chris
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2021, 140
  • [8] Partial oral antibiotic treatment for bacterial brain abscess: an open-label randomized non-inferiority trial (ORAL)
    Jacob Bodilsen
    Matthijs C. Brouwer
    Diederik van de Beek
    Pierre Tattevin
    Steven Tong
    Pontus Naucler
    Henrik Nielsen
    Trials, 22
  • [9] Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non-inferiority trial
    Abt, Dominik
    Mullhaupt, Gautier
    Mordasini, Livio
    Gusewell, Sabine
    Markart, Stefan
    Zumstein, Valentin
    Kessler, Thomas M.
    Schmid, Hans-Peter
    Engeler, Daniel S.
    Hechelhammer, Lukas
    BJU INTERNATIONAL, 2019, 124 (01) : 134 - 144
  • [10] Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT)
    Ekstrand, Joakim
    Fattah, Christian
    Persson, Marcus
    Cheng, Tony
    Nordanskog, Pia
    Akeson, Jonas
    Tingstrom, Anders
    Lindstrom, Mats B.
    Nordenskjold, Axel
    Rad, Pouya Movahed
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2022, 25 (05): : 339 - 349